Table 1.

Baseline patient characteristics.

Clinical Parameters	Total N = 21 (%)	Responders (N = 11)	Non-Responders (N = 10)
Age	33–70 (Median = 58 yrs)	33–70 (Median = 51 yrs)	46–69 (Median = 58 yrs)
Sex (M/F)	20/1 (95.2%/4.8%)	10/1 (90.9%/9.1%)	10/0 (100%/0%)
Smoking	4 (19%)	3 (27.2%)	1 (10%)
Co-morbidity (Diabetes, Hypertension and COPD)	12 (57.1%)	7 (63.6%)	5(50%)
Treatment
Partial/Radical nephrectomy	2/19 (9.5%/90.5%)	1/10 (9.1%/90.9%)	1/9(10%/90%)
Nivolumab	21 (100%)	11 (100%)	10 (100%)
Sunitinib/Adjuvant Radiation	18/0 (85.8%/0%)	18/0 (85.8%/0%)	18/0 (85.8%/0%)
RCC (B/L //U/L)	1/20 (4.8%/95.2%)	1/10 (9.1%/90.9%)	0/10 (0%/100%)
Clinical End point
Dead/Alive	3/18 (14.2%/85.8%)	1/10 (9.1%/90.9%)	2/8 (20%/80%)
Clinical complications (including Dead)/Stable	8/13 (38%/62%)	4/7 (36.3%/63.6%)	4/6 (40%/60%)
Histology
P T1	3 (14.2%)	2 (18.2%)	1 (10%)
P T2	1 (4.8%)	0 (0%)	1 (10%)
PT3	17 (80.9%)	9 (81.8%)	8 (80%)
Gross Tumor Volume	305 cc (Median)
Histology
Clear cell	18 (85.8%)	8 (72.7%)	10 (100%)
Papillary	2 (9.5%)	2 (18.1%)	0 (0%)
MIT family	1 (4.7%)	1 (9.1%)	0 (0%)
Sarcomatoid elements
Present	6 (28.5%)	2 (18.2%)	4 (40%)
Absent	15 (71.5%)	9 (81.8%)	6 (60%)
Fuhrman’s Grade
2	5 (23.8%)	3 (27.2%)	2 (20%)
3	14 (66.7%)	8 (72.8%)	6 (60%)
4	2 (9.5%)	0 (0%)	2 (20%)
Renal pelvis
Involved	7 (33.3%)	4 (36.3%)	3 (30%)
Not Involved	14 (66.7%)	7 (63.7%)	7 (70%)
LVNI
Present	12 (57.1%)	8 (72.7%)	4 (40%)
Absent	9 (42.9%)	3 (27.2%)	6 (60%)
Lymph nodes
Present	4 (19%)	3 (27.2%)	1 (10%)
Absent	17 (81%)	8 (72.8%)	9 (90%)
Gerotas fascia, ureter, and renal vessels
Involved	0 (0%)	0 (0%)	0 (0%)
Not involved	21 (100%)	11 (100%)	10 (100%)